Our technology
We at Baxiva have developed a technology that addresses the unmet need for rapid development of vaccines that target existing and emerging bacterial pathogens. Our novel chemical conjugation strategy allows the facile attachment of serotype-specific polysaccharides from gram-negative bacteria to potently immunostimulatory virus-like particles (VLPs).
Contact us
Interested in learning more? Fill out some info and we will be in touch shortly. We can’t wait to hear from you!